Novo Nordisk Fermentor

Order byBest matchMost fresh

Novo Nordisk Shares Plummet

Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook

The updated outlook "reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition," the company said.

· 10h · on MSN

Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEO, shares plunge

Fierce Pharma · 9h

Novo Nordisk names new CEO as the obesity drugmaker cuts sales, profit outlook

· 6h

European stocks close up; Novo Nordisk logs its biggest daily drop on record

European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest one-day drop of the year as Novo Nordisk's shares slid after the weight-los...

· 8h

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

· 4h

Novo Nordisk Shares Plummet as Competition Weighs on Sales

· 8h

Wegovy maker Novo's profit warning triggers $70 billion share rout

The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May o...

· 2h

Ozempic maker Novo Nordisk on track for its worst day since Black Monday

· 11h

Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance

10hon MSN

Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and named a new CEO.

Contract Pharma3h

Novo Nordisk Appoints New President & CEO

Novo Nordisk has appointed Maziar Mike Doustdar as President and CEO, effective August 7, 2025. Doustdar succeeds Lars Fruergaard Jørgensen, who will step down on the same date.

9hon MSN

Novo Nordisk appoints new CEO Maziar Doustdar

July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar steps into the role succeeding Lars Fruergaard Jorgensen, effective Aug. 7, 2025, which will also serve as Joregensens last day.

BioPharma Dive7h

Novo cuts guidance, names new CEO as obesity drug challenges mount

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its competition with rival Eli Lilly.